IDH1 and cholangiocarcinoma: Another Phase 1, multicenter study will determine the safety, pharmacokinetics, pharmacodynamics, and clinical activity of ivosidenib in advanced solid tumors, including glioma and CCA, that harbor an IDH1 mutation (NCT02073994).